Type-I Interferons in Alzheimer's Disease and Other Tauopathies.
View / Open Files
Authors
Sanford, Sophie AI
McEwan, William A
Publication Date
2022Journal Title
Front Cell Neurosci
ISSN
1662-5102
Publisher
Frontiers Media SA
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Sanford, S. A., & McEwan, W. A. (2022). Type-I Interferons in Alzheimer's Disease and Other Tauopathies.. Front Cell Neurosci https://doi.org/10.3389/fncel.2022.949340
Abstract
The detection of pathogen-associated molecular patterns can elicit the production of type-I interferons (IFNs), soluble cytokines that induce a transcriptional state inhibitory to viral replication. Signatures of type-I IFN-driven gene expression, and type-I IFNs themselves, are observed in the central nervous system during neurodegenerative diseases including Alzheimer's disease and other tauopathies, the umbrella term for diseases that feature aggregation of the cytosolic protein tau. The contribution of the type-I IFN response to pathological progression of these diseases, however, is not well-understood. The wholesale transcriptional changes that ensue from type-I IFN production can both promote protective effects and lead to damage dependent on the context and duration of the response. The type-I IFN system therefore represents a signaling pathway with a potential disease-modifying role in the progression of neurodegenerative disease. In this review we summarize the evidence for a type-I IFN signature in AD and other tauopathies and examine the role of aggregated proteins as inflammatory stimuli. We explore both the protective role of IFN against protein pathologies as well as their downstream toxic consequences, which include the exacerbation of protein pathology as a potentially destructive feed-forward loop. Given the involvement of type-I IFNs in other neurogenerative diseases, we draw comparisons with other categories of homotypic protein aggregation. Understanding how type-I IFN influences progression of AD and other tauopathies may yield important insight to neurodegeneration and identify new targets in an area currently lacking disease-modifying therapies.
Keywords
Alzheimer's disease, IFN, amyloid-beta pathology, antiviral immunity, innate immunity, tau pathology, tauopathies, type-I interferon response
Sponsorship
Alzheimer's Society studentship 488
Wellcome Trust and Royal Society Sir Henry Dale Fellowship 206248/Z/17/Z
UK Dementia Research Institute Fellowship
Lister Institute of Preventative Medicine
Funder references
Wellcome Trust (206248/Z/17/Z)
Lister Institute of Preventive Medicine (Unknown)
Alzheimer's Society (488 (AS-PhD-18b-018))
UK Dementia Research Institute (Unknown)
Identifiers
External DOI: https://doi.org/10.3389/fncel.2022.949340
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338174
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk